Liberel Mite (Desogestrel, Ethinylestradiol)

Desogestrel/Ethinylestradiol, the active ingredient in Liberel Mite, is a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It works by inhibiting ovulation and creating cervical mucus changes, thereby preventing pregnancy in women of reproductive age.

GNH USA supplies Liberel Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics. The company adheres to EU Good Manufacturing Practice standards and provides full documentation for importers.

Liberel Mite, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception.

- Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. - Management of menstrual disorders: helps regulate cycle length and reduce heavy bleeding. - Treatment of moderate acne: reduces androgen‑driven skin lesions in eligible patients.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Breast tenderness: discomfort or swelling of breast tissue. - Headache: occasional throbbing or tension‑type pain. - Spotting: irregular breakthrough bleeding, especially during the first cycles. - Mood changes: mild irritability or emotional fluctuations.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Hypertension: significant increase in blood pressure. - Liver disorders: benign hepatic adenoma or cholestatic jaundice. - Gallbladder disease: formation of gallstones or cholecystitis. - Severe allergic reaction: anaphylaxis, angioedema, or urticaria.

Before initiating therapy, clinicians should evaluate individual risk factors and counsel patients on safe use.

- Medical assessment: screen for history of thromboembolism, cardiovascular disease, or smoking. - Age consideration: avoid use in women over 35 who smoke heavily. - Liver function: monitor in patients with hepatic impairment. - Migraine history: caution in those with migraine with aura. - Concomitant medications: review for drugs that may affect hormonal efficacy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Combined oral contraceptives can be affected by several drug classes.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Antiretroviral protease inhibitors (e.g., ritonavir): can alter hormone levels. - St. John's wort: potent CYP3A4 inducer that may compromise efficacy.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole, itraconazole): may increase hormone concentrations. - Selective serotonin reuptake inhibitors (SSRIs): occasional alteration of bleeding patterns. - Antihypertensives (e.g., ACE inhibitors): monitor blood pressure as hormonal changes can affect control.